Genetic Advantage
In this edition of the Smart Investor newsletter, we spotlight a biotechnology platform translating genetic science into durable growth. But first, let’s review the latest Smart Portfolio developments.
1
Portfolio News and Updates
❖❖❖ Portfolio Note: Addressing AI Bubble Fears
The past week was brutal for stocks in general and for many Smart Portfolio holdings in particular, as data center trade saw its steepest sell-off since April’s tariff tantrum. Much of the downswing was tied to worries about Oracle’s (ORCL) capex and Broadcom’s (AVGO) margins, but the underlying driver remained the same: the persistent fear that the entire AI trade has ballooned into a bubble that may burst at any moment. Stocks across the AI value chain – including chipmakers, network-gear vendors, memory providers, AI-exposed REITs, electrical and mechanical contractors, and data-center energy suppliers – were deep in the red.
For at least the past two years – ever since valuations of AI-related stocks moved into elevated territory – bubble fears have simmered below the surface, periodically resurfacing when triggered by one catalyst or another: Fed-rate moves, macro worries, DeepSeek headlines, trade-war escalation, Microsoft (MSFT) lease-freeze rumors, OpenAI funding questions, Nvidia sell-offs, and more. Up until now, every meaningful drawdown was quickly absorbed by dip-buyers before valuations had a chance to deflate meaningfully. However, history tells us there will eventually be a sell-off that does not get rescued. Ideally, that moment arrives as a healthy correction rather than a full-blown bear market. Until then, the question of whether we are in a bubble remains unresolved – and that uncertainty alone is enough to keep investors on edge.
Markets are cyclical, and no rally lasts forever. That does not invalidate the underlying case for the rally – in this instance, generative AI and its ecosystem. Few dispute that roughly three years ago OpenAI unleashed a genuinely transformative technology, or that we are in the early innings of a new industrial cycle already reshaping productivity, capital allocation, and competitive dynamics across the economy. AI bubble fears are therefore valuation-driven, not rooted in doubts about the technology itself.
What is being questioned is the timing and magnitude of returns on the enormous sums now being invested. The implicit market logic seems to be: “If the returns materialize fast enough, this is not a bubble.” To date, many companies at the center of AI spending have delivered strong – often exceptional – earnings growth, with little evidence of near-term deterioration. In several cases, valuations look far less extreme once discounted against that growth. Even on an undiscounted basis, large-cap tech valuations remain well below levels seen during prior periods of true market euphoria.
At the same time, AI-driven revenue growth has so far been dwarfed by investment. Microsoft, Alphabet, Amazon, and Meta alone plan to spend more than $400 billion on data centers and related infrastructure over the next twelve months. Historically, major market bubbles have often been preceded by sharp spikes in total investment and debt issuance – a pattern that is at least partially visible today, as hyperscalers accelerate capex and companies like Oracle (as well as Meta, Alphabet, Amazon, Microsoft, and many others) are leaning more heavily on their balance sheets to fund this rapid expansion.
Layer on year-end portfolio rebalancing and renewed interest-rate debates, and the result is another phase of elevated tech volatility. Whether the current AI sell-off proves to be a short-term shakeout, a broader correction, or the early stage of a deeper rotation remains unclear. Panic is unwarranted, but vigilance is essential.
1
❖ That is why we are watching Oracle (ORCL) particularly closely. Although we firmly believe the company has the potential to grow many times over, its near-term investment case now hinges on execution: converting an enormous backlog into revenue without accumulating liabilities at a pace that risks a credit downgrade. Such an outcome could trigger higher borrowing costs, further leverage, and a negative feedback loop in investor sentiment.
Oracle’s fiscal Q2 2026 was a mixed bag. Adjusted EPS surged 54% year-over-year to $2.26, well ahead of expectations. However, a sizable portion of that upside came from a one-time $2.7 billion sale of its Ampere chip interest, which inflated pretax earnings. Revenue reached $16.1 billion, up 14% year-over-year but slightly below consensus, with cloud revenue rising 33% to $8 billion. Cloud-infrastructure revenue jumped 66%, driven by a 177% increase in GPU-related revenue. Meanwhile, Oracle’s multiyear backlog – remaining performance obligations, or RPO – ballooned to over $523 billion, up $68 billion sequentially and 433% year-over-year.
Despite that surge, cloud-infrastructure revenue still fell short of estimates. While supply constraints are affecting all hyperscalers, the miss came at an inopportune moment, as investors were already questioning Oracle’s ability to translate backlog into near-term revenue. That skepticism intensified after a Bloomberg report suggested Oracle had pushed back completion dates for some OpenAI-related data centers. Although management denied the claim, the episode underscored how sensitive the narrative has become. Seeding doubts about potential delays to data-center completions is especially harmful in Oracle’s case, as these would mean delays in translating orders on the books into real revenues.
As a result, the RPO surge failed to reassure investors this time around. The market appears to be drawing a distinction between signing massive cloud contracts and financing, building, and delivering them at scale. Oracle’s capex has come in higher than expected, and fiscal Q2 revealed deeper-than-anticipated free-cash-flow pressure, with trailing twelve-month FCF falling to roughly negative $10 billion. Management’s decision to raise full-year capex plans from $35 billion to $50 billion only heightened concerns.
Oracle’s cloud push has successfully repositioned the company from a slow-growth software vendor into a credible fourth hyperscaler. Unlike its peers, however, Oracle is attempting this transition without the cushion of a massive existing cash reserve. Demand is clearly there – as reflected in RPO – but delivering on it requires sustained capital intensity and near-term margin sacrifice. If executed well, OCI could ultimately place Oracle among the largest technology platforms globally. The market’s unease stems from a simpler question: can Oracle execute flawlessly under these financial constraints?
Another source of concern is Oracle’s reliance on OpenAI, its flagship customer and partner in the Stargate project. OpenAI plans to spend an estimated $1.4 trillion over the coming years, despite not expecting to turn profitable until around 2030. While funding has flowed freely so far, any disruption to that financing ecosystem could reverberate across the AI infrastructure stack.
1
❖ We are far less concerned about Broadcom’s (AVGO) setup – a view echoed by Wall Street consensus. Analyst price-target increases flooded in even as the stock sold off sharply following a double beat and raise. In fact, the world’s second-largest semiconductor company experienced its worst post-earnings drop on record.
AVGO delivered one of the cleanest earnings reports in large-cap tech in recent years. In fiscal Q4 2025, revenue rose 28% year-over-year to a record $18 billion, driven by a 74% surge in AI semiconductor sales. Adjusted EPS climbed more than 37% to $1.95, comfortably ahead of consensus. The company secured an additional $11 billion custom-chip order from Anthropic, following a $10 billion order last quarter, and added a fifth custom-chip customer with a $1 billion commitment. AI backlog expanded to $73 billion, largely scheduled for delivery over the next eighteen months – and this figure continues to grow constantly with more orders rolling in, supporting the outlook for continued acceleration in AI growth.
For the full fiscal year, revenue grew 24% to $64 billion, with AI chips and VMware integration driving results. AI revenue jumped 65% to $20 billion, while infrastructure-software revenue climbed 26% to $27 billion. Adjusted EPS surged 40% to $6.82, margins expanded, and free cash flow rose 39%. Management guided for continued momentum in fiscal Q1 2026, forecasting revenue of $19.1 billion, up 28% year-over-year, with AI semiconductor revenue expected to double to $8.2 billion.
Investor anxiety focused less on results – however stellar – and more on optics. Broadcom declined to provide explicit fiscal 2026 AI guidance, with CEO Hock Tan describing it as a “moving target,” and warned of near-term margin pressure as lower-margin AI systems represent a larger revenue mix.
We agree with analysts who attribute the sell-off primarily to broader AI-trade jitters rather than company-specific deterioration. Absent a structural breakdown in AI trade, Broadcom’s fundamentals remain exceptionally strong. Even in a prolonged tech downturn, diversified, cash-rich, innovation-led businesses like AVGO have historically recovered faster and compounded more reliably than the broader market over time.
1
❖ Alphabet (GOOGL) enters year-end with strengthening operating signals and incremental balance-sheet optionality. On the fundamentals side, TD Cowen and JPMorgan both raised price targets following stronger-than-expected indicators from Google’s AI rollout. Survey data point to accelerating adoption of Gemini 3, rising engagement in AI Mode and AI Overviews, and increasing overlap between ChatGPT users and Gemini users – reinforcing confidence that AI is enhancing, not cannibalizing, core Search usage. JPMorgan reiterated GOOGL as a top pick into 2026, citing durable low-to-mid-teens revenue growth across internet megacaps.
At the same time, Alphabet stands to benefit from a non-operating tailwind. A recent SpaceX tender offer implying an approximately $800 billion valuation could trigger another unrealized gain on Alphabet’s long-held private stake, similar to the accounting uplift recorded earlier this year. While non-cash and secondary to the core thesis, such gains can support reported earnings and near-term sentiment. Together, improving AI-driven engagement and incremental upside from private holdings strengthen Alphabet’s risk-reward profile into year-end.
1
❖ IBM (IBM) continues to reinforce its position as an enterprise-first AI platform, with recent developments underscoring depth. Stanford University ranked IBM’s Granite 3.3 model first in its 2025 Foundation Model Transparency Index, highlighting IBM’s emphasis on governance, data traceability, and real-world deployability – attributes that matter most to regulated enterprises. This focus carried into the release of Granite 4.0, which remains open source, security-certified, and efficient enough to run on modest hardware.
On the product side, IBM launched Project Bob, an AI-powered coding assistant designed for complex enterprise environments. Unlike generic copilots, Bob prioritizes compliance, cost control, and workflow integration, already supporting more than 10,000 internal developers ahead of a public rollout.
Strategic partnerships add further weight. IBM’s collaboration with Pearson extends its AI footprint into workforce training and reskilling, embedding watsonx tools into education and enterprise learning systems. Together with the pending Confluent acquisition, these moves signal a consistent strategy: embedding AI into mission-critical data, software, and human workflows, where durability and trust drive long-term adoption.
1
❖ Pfizer’s (PFE) stock has taken a beating after its initial 2026 guidance came in modestly below analyst expectations, reviving concerns about the pace of its post-Covid reset. Management outlined adjusted earnings of $2.80-3.00 per share and revenue of $59.5-62.5 billion for next year, both slightly below consensus, reflecting a continued decline in Covid-related products and the early stages of a multi-year loss-of-exclusivity cycle. In isolation, the numbers look uninspiring – and in an already nervous market, that was enough to trigger a sharp reaction.
However, upon closer inspection, the message is less troubling than the headlines suggest. The bulk of the weakness stems from a roughly $1.5 billion year-over-year drop in Covid sales and another $1.5 billion tied to patent expirations across legacy drugs – pressures that were already well understood and largely front-loaded. Excluding Covid products, Pfizer is guiding to low-single-digit operational growth, indicating that the core portfolio remains broadly stable even as legacy revenues roll off.
At the same time, management is leaning hard on cost discipline. Pfizer is ahead of its restructuring targets, with more than $7 billion in cumulative savings expected by 2027, much of it realized by next year. That discipline is helping offset revenue headwinds while the company invests through the trough. In parallel, Pfizer continues to build toward its next growth phase, positioning its oncology, obesity, and immunology pipeline for a rebound later in the decade.
Morgan Stanley added to the cautious tone around Pfizer’s near-term outlook, slightly trimming its price target while reiterating a “Hold” rating. The firm expects 2026 to mark a shift away from policy-driven headlines and back toward fundamentals, where Pfizer still faces a digestion period following Covid normalization, patent expirations, and heavy reinvestment. Importantly, the call is not bearish: the revised target still implies upside from current levels, and Morgan Stanley views political and regulatory noise as easing rather than intensifying. Other analysts are incrementally more constructive. HSBC recently raised its target and placed Pfizer in its growth-oriented ideas list for 2026, arguing the sector could benefit from rotation if technology volatility persists.
Taken together, the Street’s message is consistent: 2026 looks less like a reset point and more like a bridge year. Growth is constrained, visibility is limited, but the reset is increasingly well understood – and expectations now sit low enough to leave room for upside as execution improves.
1
1
Portfolio Stocks Under Review
❖ KKR & Co. Inc. (KKR) remains under review, not because the investment case has weakened, but because the stock now sits at the intersection of strong fundamentals and heightened market sensitivity.
Operationally, the picture continues to improve. KKR is executing as one of the most diversified and fastest-scaling platforms in alternative asset management, with momentum across private equity, credit, infrastructure, and insurance via Global Atlantic. Fee-related earnings are compounding, realizations are accelerating, and leading sell-side firms have reinforced their conviction, with multiple Overweight and Buy ratings reiterating KKR as a top pick for a capital-markets recovery. Recent commentary highlights a visible pipeline of monetizations, rising carry realization, and sustained fundraising strength heading into 2026.
Importantly, several perceived risks are becoming better framed rather than worsening. KKR’s participation – alongside Blackstone, Apollo, and Ares – in the Bank of England’s system-wide stress test of private credit reduces opacity concerns and reinforces its position as an institution-grade operator with robust risk management. This directly addresses one of the lingering overhangs on the sector.
The challenge remains external rather than company-specific. KKR’s stock is inherently volatile, and recent gains have pushed momentum indicators into overbought territory amid a market that is increasingly reactive and risk-averse. While valuation is not extreme relative to peers – and arguably more reasonable than many large alternatives – it is still premium enough to amplify investor nervousness during periods of macro anxiety. In an outright risk-off or bear-market scenario, stocks like KKR tend to de-rate regardless of execution.
At this stage, we see no reason to exit. The balance of evidence supports holding through near-term volatility to see whether improving capital-markets conditions and realization trends translate into more durable share-price momentum. However, given the stock’s sensitivity to sentiment, KKR remains under review until market conditions either stabilize enough to support its upside or deteriorate in a way that materially changes the risk-reward profile.
In short, KKR still offers the strongest long-term growth potential in alternatives – but in the current environment, patience and close monitoring remain the prudent course.
1
1
Portfolio Earnings and Dividend Calendar
❖ The Q3 2025 earnings season is over, but some Smart Portfolio companies have different fiscal calendars. These include Jabil (JBL), scheduled to report its fiscal Q1 2026 today.
❖ The ex-dividend date for Broadcom (AVGO) is December 22.
w
1
New Buy: Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals, Inc. is a research-driven biotechnology company that occupies a distinctive position within the global biopharma landscape. Rather than pursuing broad therapeutic breadth, Vertex has built its identity around deep scientific focus, translating molecular insight into medicines for serious, genetically defined diseases. The company is best known for establishing a durable leadership position in cystic fibrosis, where it effectively reshaped the standard of care and demonstrated how precision medicine can move from theory to scalable reality. That foundation has allowed Vertex to operate more like a platform than a single-product biotech – combining discovery, clinical development, manufacturing, and commercialization under one roof. With a culture rooted in biology-first decision-making and long development cycles, Vertex functions as a specialist innovator within the industry – less exposed to short-term market noise and more aligned with sustained therapeutic impact.
1
Rewriting the Code
Vertex Pharmaceuticals was founded in 1989 with an ambition that set it apart from the start – to apply rigorous molecular science to diseases that had long resisted conventional drug development. In its early years, Vertex operated as a research-centric biotech, advancing a broad pipeline and partnering with larger pharmaceutical companies to fund discovery. The strategy produced scientific credibility but uneven commercial results, and by the late 2000s the company faced a familiar biotech crossroads: refine its focus or remain spread thin across too many fronts.
That inflection point arrived with a deliberate pivot toward genetically defined diseases, most notably cystic fibrosis. Rather than treating symptoms, VRTX concentrated on correcting the underlying biological mechanisms, a shift that reshaped both its research model and its long-term economics. This approach fundamentally altered the course of cystic fibrosis itself, transforming a once-fatal childhood disease into a manageable chronic condition for a large share of patients and materially extending both life expectancy and quality of life. In doing so, Vertex moved beyond incremental improvement and effectively redefined the standard of care for the disease. As successive breakthroughs moved from lab to clinic and into widespread use, VRTX transitioned from a development-stage biotech into a fully integrated commercial organization, building internal capabilities across manufacturing, regulatory affairs, and global distribution.
The past five years mark a second transformation – from a highly successful cystic fibrosis specialist into a broader innovation platform. With its core franchise generating durable cash flows, Vertex began reinvesting aggressively into new therapeutic areas, internal technologies, and external collaborations. Its platform strategy reflects the application of Vertex’s core strengths – human genetics, protein modulation, and mechanism-driven drug design – across multiple disease categories, including kidney disease, pain, metabolic disorders, and immune-mediated conditions, rather than remaining confined to pulmonary indications.
The company expanded its research engine through partnerships with academic institutions and biotechnology peers, while selectively acquiring capabilities that strengthened its long-term pipeline rather than chasing near-term revenue. That discipline softened in 2024, when Vertex announced its acquisition of Alpine Immune Sciences, a clinical-stage biotech focused on immune and kidney diseases – a targeted move intended to deepen Vertex’s reach in areas where genetic insight and biologic precision could support future growth.
Strategic collaborations became central to this evolution. VRTX aligned with gene-editing pioneers like CRISPR Therapeutics and Entrada Therapeutics to push into complex genetic disorders, invested in next-generation cell and RNA technologies, and broadened its clinical footprint beyond pulmonary disease. At the same time, management maintained a clear preference for partnerships and internally funded programs over large-scale acquisitions, preserving balance-sheet flexibility and research autonomy.
Operationally, Vertex also matured. Manufacturing processes were scaled and modernized to support more complex therapies, while data-driven approaches increasingly informed clinical trial design and patient selection. These advances reduced development risk and improved the probability of success as the company moved into larger and more diverse indications.
What ties Vertex’s history together is discipline. It exited programs that did not meet scientific or commercial thresholds, doubled down on areas where biology and execution aligned, and resisted pressure to diversify prematurely. That discipline allowed Vertex to evolve from a focused cystic fibrosis champion into a platform company with multiple shots on goal – spanning rare genetic diseases, chronic conditions, and adjacent biologic pathways – without losing the scientific rigor that defined its early years. Today’s Vertex reflects that journey – a company shaped by long development cycles, deep biological insight, and a willingness to transform itself when the opportunity set demanded it.
1
Scaling the Science
Vertex operates a focused but expanding biopharmaceutical model built around one core idea – solve the biology first, then scale globally. Today, the company’s business is anchored by cystic fibrosis franchise, generating roughly 90% of total revenue. However, the operating model has widened meaningfully over the past several years as VRTX pushes into pain, kidney disease, and gene-editing therapies.
Cystic fibrosis treatments remain the foundation. Vertex’s CF franchise is protected by deep intellectual property, global reimbursement, and continual lifecycle management, allowing it to treat nearly 95% of the CF population worldwide. The business has matured into a predictable, high-margin cash engine rather than a growth-at-any-cost model, providing the capital base to fund diversification. The latest iteration of this strategy is ALYFTREK,1 which is gaining traction among both CFTR-modulator-naïve patients2 and those switching from earlier therapies, with the largest incremental opportunity now outside the U.S., particularly in Europe.
Beyond CF, Vertex is building what management increasingly describes as a second growth layer. The most advanced commercial expansion is JOURNAVX,3 a non-opioid acute pain therapy. While it currently contributes only a low-single-digit share of revenue, its strategic importance is outsized. Prescription volume has scaled quickly, access now covers more than half of insured U.S. lives, Medicaid coverage has expanded state by state, and discussions with large pharmacy benefit managers are ongoing. Vertex is also positioning JOURNAVX for longer-duration pain settings, including diabetic peripheral neuropathy, where two Phase 3 programs are underway.
Gene editing represents a third pillar. CASGEVY,4 Vertex’s first commercial gene-editing therapy, is still early in its rollout and contributes modest revenue today, but its global approval footprint continues to expand. Recent pediatric data and planned regulatory submissions for younger patients extend the addressable population, while reimbursement agreements in Europe are translating clinical promise into real-world access. Operational complexity remains a gating factor, but the platform is now moving from proof of concept toward scale.
CASGEVY has received a “priority drug” badge from the FDA in November, which expedites review for future submissions, cutting timelines from 10-12 months to 1-2 months and supporting planned expansions and enhancing market expansion amid competition in gene therapies, potentially bringing forward the expected revenue boost. This adds to SUZETRIGINE’s (acute pain medicine) priority status, received earlier this year.
The most consequential diversification effort, however, are kidney disease treatments. Vertex’s renal portfolio is designed to replicate its CF playbook – start with genetically and biologically defined disease, then expand indications. In immune-driven kidney conditions, Vertex has reported meaningful reductions in protein leakage and stabilized kidney function, supporting an accelerated regulatory path and expanding its reach beyond pulmonary disease. In parallel, Inaxaplin5 targets APOL1-mediated kidney disease,6 an untreated genetic condition. Inaxaplin, along with another investigational kidney disease treatment, has received a Breakthrough Therapy Designation (BTD) from the FDA, enabling faster timelines. Together, kidney programs represent the largest future non-CF revenue opportunity and a meaningful driver of mix change over time.
What distinguishes Vertex’s business model is restraint. The company has avoided broad acquisitions, preferring partnerships, internal development, and selective capability expansion – most notably with Alpine Immune Sciences – while maintaining a net-cash balance sheet. That discipline allows Vertex to absorb launch costs, navigate reimbursement friction, and pursue multiple growth avenues without compromising the durability of its core franchise.
—
1 – ALYFTREK – next-generation cystic fibrosis therapy; commercially launched with global reimbursement expansion underway.
2 – CFTR-modulator-naïve – cystic fibrosis patients who have not previously received CFTR-targeted treatments, either because they were newly eligible or lacked access. CFTR (cystic fibrosis transmembrane conductance regulator) is the protein whose malfunction causes cystic fibrosis.
3 – JOURNAVX (suzetrigine) – non-opioid acute pain drug; FDA-approved, commercially launched, expanding Medicaid and payer coverage; Phase 3 trials underway for diabetic peripheral neuropathy.
4 – CASGEVY – CRISPR/Cas9 gene-editing therapy for sickle cell disease and beta thalassemia; commercially approved in multiple regions; pediatric submissions planned.
5 – Inaxaplin – targeted therapy for APOL1-mediated kidney disease; in Phase 3 development.
6 – APOL1-mediated kidney disease – a genetically driven kidney disorder with no approved treatments today, primarily affecting patients of African ancestry.
—
1
Funded to Expand
Vertex’s financial profile in 2025 reflects a company operating from a position of strength – preserving one of the most profitable franchises in large-cap biotechnology while deliberately funding its next phase of growth.
In the third quarter of 2025, VRTX reported revenue of $3.08 billion, up 11% year-over-year and slightly above the consensus, driven primarily by the cystic fibrosis franchise and supplemented by early contributions from newer launches. Adjusted earnings per share came in at $4.80, up 10% year-over-year, and notably ahead of analyst expectations clustered around $4.57. The earnings beat was driven less by top-line surprise than by operating leverage embedded in the core CF business.
Profitability remains a defining characteristic. Net margins in the quarter sat in the low-30% range, an unusually high level for a research-intensive biotechnology company. That margin profile has held steady over recent quarters, even as Vertex increased spending behind commercial launches and late-stage development programs. The result is a business that continues to convert revenue growth into earnings growth without sacrificing financial discipline.
Over the first nine months of 2025, VRTX generated just over $3 billion in operating cash flow, while capital expenditures remained comparatively modest. The company carries no meaningful long-term debt, leaving it with substantial balance-sheet flexibility.
Management is using that flexibility to increase investment aimed at driving growth beyond cystic fibrosis, including spending on late-stage kidney disease programs, expansion of the acute pain franchise, gene-editing scale-up, and related commercial and manufacturing infrastructure. Those investments are being funded entirely from internally generated cash, with the cystic fibrosis business continuing to cover both ongoing operations and incremental growth initiatives.
Those investments are front-loaded relative to their revenue contribution. Most of the spending supports programs that are still scaling commercially or approaching regulatory and access milestones, rather than businesses already contributing meaningfully to earnings. As a result, the financial impact is expected to emerge gradually, through incremental diversification and a slow shift in revenue mix, rather than as a sharp acceleration in reported growth.
Guidance reflects that framing. Management reaffirmed full-year 2025 revenue guidance of $11.9-12.0 billion, implying approximately 8-9% year-over-year growth, and maintained adjusted operating expense guidance of $5.0-5.1 billion. The steady expense range, despite multiple active launches and late-stage programs, suggests confidence in execution rather than an effort to pull growth forward.
Looking ahead, company commentary and analyst expectations align around 2026 as a year of mix evolution rather than a sharp inflection. The cystic fibrosis franchise is expected to remain the earnings backbone, while pain, kidney disease, and gene-editing therapies begin to contribute more visibly as reimbursement broadens and launch costs normalize. Analysts broadly expect continued high-single-digit revenue growth and low-double-digit adjusted earnings growth next year, assuming no major clinical disruptions.
One underappreciated factor in the current policy environment is manufacturing exposure. VRTX produces the majority of its cystic fibrosis therapies in the United States, reducing vulnerability to import tariffs and supply-chain disruption under a more protectionist trade stance. That domestic footprint significantly reduces risk, reinforcing earnings visibility at a time when policy volatility has returned to markets.
Taken together, Vertex’s financials describe a consistent pattern: a high-margin, cash-generative core business funding expansion into new therapeutic areas, supported by a debt-free balance sheet and guidance that prioritizes credibility over optimism. It is a financial structure designed to compound steadily rather than chase short-term acceleration.
1
Editing the Narrative
Vertex’s closest peers sit within the top tier of U.S.-listed biotechnology, where long-term valuation is driven by franchise durability, pipeline execution, and disciplined reinvestment. Regeneron stands as the most direct comparator – a science-led biotech built around a dominant core franchise and sustained R&D intensity. Amgen anchors the group at larger scale, illustrating how cash generation and portfolio breadth shape returns as growth matures. Gilead adds useful context as a company that has already navigated a major franchise transition and is now delivering steadier performance through its HIV base and expanding oncology portfolio. Together, these peers frame the spectrum of outcomes the market assigns to large-cap biotech, providing a clean lens through which to assess VRTX’s positioning.
Year-to-date performance across the group has been positive but uneven, shaped by Fed rate cuts, shifting drug-pricing policy, FDA decisions, M&A activity, and renewed investor rotation into biotech as a defensive growth segment. The dispersion has been wide. Gilead has led the group as its resilient HIV franchise and incremental approvals supported momentum. Amgen followed, buoyed by volume-driven growth and investor enthusiasm around its obesity pipeline. Vertex sits in the middle with an approximately 13% year-to-date gain – steady and reliable, much like its business – while Regeneron has lagged amid intensifying competition and more uneven pipeline readouts.
Those performance differences help explain current valuation spreads, but they also obscure where Vertex now stands fundamentally. Relative to peers, VRTX offers one of the most compelling growth–profitability combinations. Revenue growth over the past year has been second only to Amgen, while forward sales growth is projected to lead the peer set. EBITDA growth has been the strongest in the group and is expected to remain so over the next year, with EPS growth likewise forecast to outpace peers. At the same time, Vertex’s net income margin, return on assets, and return on total capital rank at or near the top of the group.
Against that backdrop, the valuation gap looks less like a reflection of fundamentals and more like a lag in recognition. Vertex does trade at a premium on headline multiples – particularly trailing P/E and Price/Sales – but those figures miss two key dynamics. First, near-term investment is dampening reported earnings even as underlying growth accelerates. Second, when viewed through a forward and growth-adjusted lens, much of that premium fades.
On forward non-GAAP earnings, Vertex’s multiple compresses meaningfully over the next two years, converging toward peers that are growing at materially slower rates. More revealing is the growth-adjusted view: Vertex carries the lowest forward PEG ratio in the group by a wide margin, reflecting faster expected earnings growth alongside sustained margin strength. In effect, the market is pricing Vertex closer to mature biopharma, despite forecasts that point to superior earnings expansion.
The same pattern holds across enterprise-value metrics. Vertex trades at a higher EV/Sales ratio today, but that multiple sits atop the strongest margins and most attractive forward growth profile in the peer set. On EV/EBITDA, the premium narrows substantially on a forward basis, particularly relative to companies where EBITDA growth is flattening or increasingly reliant on cost discipline rather than business momentum.
Importantly, these multiples are not being supported by leverage. Vertex operates with no debt, funding investment from operating cash flow rather than financial engineering. That contrasts with peers where lower headline multiples coexist with slower growth, heavier capital returns, or balance sheets that are already optimized rather than optional.
Seen in that light, Vertex does not appear expensive so much as temporarily miscategorized. The stock is still being valued like a single-franchise compounder, while its fundamentals increasingly resemble a platform business with multiple growth vectors and a long reinvestment runway. As execution in pain, kidney disease, and gene editing therapies becomes more visible in reported results, VRTX’s current valuations look increasingly misaligned with the breadth of its growth drivers.
1
Investing Takeaway
Vertex Pharmaceuticals stands out as a high-quality compounder built on rare scientific credibility and unusually strong execution. The company combines a resilient core franchise with a growing set of diversification drivers, allowing it to fund long-term expansion without sacrificing financial discipline. Management’s strategy is deliberate rather than promotional – prioritizing biologically validated targets, measured launches, and reinvestment that compounds future optionality. As newer programs mature, Vertex is steadily reshaping its growth mix while preserving margins, balance-sheet strength, and strategic flexibility. The stock remains positioned for upside as the business broadens and investor perception catches up to the evolving earnings profile. For investors seeking exposure to innovation with durability and downside protection, Vertex offers a compelling risk-reward setup.
1
1
New Sell: Uber Technologies (UBER)
We are exiting Uber Technologies not because the business case has weakened, but because the stock’s near-term risk profile no longer fits our portfolio construction in a market that has turned increasingly unstable.
Uber’s fundamentals remain strong. The company delivered an excellent Q3 2025, with double-digit revenue growth, sharply improving profitability, and a cash-generation profile that increasingly resembles that of mature platform leaders. Engagement across mobility, delivery, and subscriptions continues to deepen, while partnerships across autonomous technology and restaurant infrastructure reinforce Uber’s long-term optionality. On valuation alone, the stock still screens as attractive relative to its growth and margin trajectory.
The issue is not execution – it is timing and sentiment. Despite a strong earnings report, Uber sold off, signaling that expectations had moved ahead of what even solid results could satisfy. That reaction marked a shift: the stock has become more sensitive to marginal disappointment and external noise, even when core performance remains intact. In a market currently marked by sharp rotations, elevated macro anxiety, and heightened scrutiny of technology platforms, that sensitivity matters.
The recent escalation of regulatory pressure around Uber One billing practices adds another layer of uncertainty, as FTC and a coalition of 21 states escalated their legal fight against the ride‑hailing giant. While this issue is unlikely to impair Uber’s long-term economics or competitive position, it has arrived at a moment when markets are reacting aggressively to any perceived risk. In a calmer environment, such headlines might have been absorbed with limited impact. In the current one, they amplify volatility and reinforce downside asymmetry in the short term.
Importantly, this decision reflects portfolio balance as much as stock-specific risk. Our exposure to tech-driven volatility has increased, and Uber – despite being undervalued on fundamentals – now contributes more to near-term swings than to incremental upside. With the stock having rebounded from its post-earnings lows, we view this as a rational point to lock in gains and reduce risk.
This is not a permanent exit. Uber remains a high-quality platform with durable growth drivers, improving margins, and meaningful long-term optionality. We fully expect to revisit the name once market conditions stabilize and sentiment resets. For now, stepping aside preserves capital and flexibility – and positions us to re-enter when clarity, rather than anxiety, is driving price action.
1
1
Smart Investor’s Winners Club
The 30% Winners Club represents stocks from the Smart Investor Portfolio that have risen at least 30% since their purchase dates.
It was a difficult week, but our Club weathered it well, still boasting 19 members: AVGO, GE, ANET, TSM, EME, HWM, APH, ORCL, PH, IBKR, GOOGL, CRWD, VRT, IBM, MTZ, RTX, BK, MS, and CSCO.
The first contender for the Club’s entry is now JPM with a 29.00% gain since purchase. Will it join the Club, or will another stock outrun it to the finish line?
1
1
|
